Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Otulfi® (ustekinumab-aauz) by Fresenius Kabi Now FDA-Approved as an Interchangeable Biosimilar

the U.S. since March 2025. Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23, which play an important role in inflammatory and immune responses. The FDA approval of Otulfi...

Osteo Bi-Flex® Adds Plant-Based Omega-3s to Promote Whole Body Health and Wellness

Osteo Bi-Flex®, the number one pharmacist-recommended joint care supplement brand1 introduced its new Osteo Bi-Flex® Advanced Omega-3 Joint Complex supplement. This new formula helps support joint and whole body health by combining 100 mg of Joint...

Research from Noster finds that a gut bacteria-derived molecule can shrink fat cells and improve metabolism

to a new mechanism by which microbiome-derived compounds may help combat obesity and related diseases. The compound—HYA (10-hydroxy-cis-12-octadecenoic acid)—is made when certain gut bacteria, including Lactobacillus, metabolize linoleic acid, a...

Kimera® Labs named a semifinalist in the $101 million XPRIZE Healthspan competition for pioneering innovations in healthy aging

the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious $101 million XPRIZE Healthspan competition. This milestone recognizes Kimera's groundbreaking work in developing cutting-edge...

Rein Therapeutics announces the initiation of the RENEW Phase 2 trial of LTI-03 in patients with IPF

fibrosis indications, announced that the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis (IPF), has been initiated with screening and recruitment...

Viralgen Partners with Trogenix to Advance AAV Gene Therapy for Glioblastoma

developing innovative cancer therapies. As part of this partnership, Viralgen successfully scaled-up and completed in under 12 months a good manufacturing practice (GMP) clinical trial material batch of Trogenix's rAAV gene therapy, TGX-007,...

INBRAIN Neuroelectronics has been awarded a €4 million grant from Spain’s PERTE Chip Program to advance graphene-based brain-computer interfaces

The Ministry provisionally awarded €53.2 million in funding on May 5, 2025, to support 37 breakthrough projects across 11 autonomous communities. INBRAIN’s project was one of several selected for their high-impact potential in areas including...

At DDW’25, NImmune Biopharma will present the first-ever head-to-head clinical and translational results for Omilancor versus the leading anti-TL1A in IBD, demonstrating superiority and complementarity

and translational results from two studies for omilancor, a Phase 3 first-in-class LANCL2 agonist versus the leading anti-TL1A candidate currently also in Phase 3 development for ulcerative colitis (“UC”). The new findings demonstrate that once...

ZEISS Unveils AI-Powered Research Data Platform in Collaboration with Boehringer Ingelheim to Advance the Future of Personalized Eye Care

discoveries to combat vision problems and improve people's lives." About Zeiss: Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology...

SK Life Science Labs Announces Nature Communications Publication of Breakthrough Molecular Glue Research Advancing Cancer Immunotherapy

around the world with a shared commitment to reducing global greenhouse gas emissions. SK Group companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME's 100 Most...

The Ohio State University and TAE Life Sciences have formed a landmark collaboration to advance boron drug innovation for precision cancer therapy.

on a global scale.” The initial focus of the collaboration will be the preclinical evaluation of TLS’s proprietary boron-10 drugs in cellular and animal models, leveraging Ohio State’s specialized neutron source optimized for BNCT research. In...

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy, SNE-101. This is the first exosome-based therapy in Korea to enter...

PCI Pharma Buys Ajinomoto Althea as Part of $1B Plan to Expand Injectable Drug Manufacturing in the U.S

facility featuring twin lyophilizers and a state-of-the-art large-scale isolator filling line compliant with Annex 1. That facility will be GMP ready this summer; since the plant’s 2022 groundbreaking, PCI has methodically developed...

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National...

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

interim results from its first-in-human study of XmAb942. A high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn’s...

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100's potent neuroprotective properties Mark Bazett will be joined by Jim Pankovich, EVP Clinical Development, and Ashish Kumar,...

At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

outcomes with transformative global implications. Broad and Effective Antibody Response: LHNVD-303 generated high-titer IgG1 antibodies in both mice and pigs against LPS, PGN, and LTA, confirming the ability to target conserved epitopes. Antisera...

Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s...

Endo's New Spatial Computing Injection Simulator for Peyronie's Disease Creates Immersive Learning Environment for Urology Specialists

the treatment of real patients with XIAFLEX, which represents an important treatment option to help appropriate patients.1 This is the second time Endo has used the power of spatial computing (also called "mixed reality") to create an immersive...

Optune Lua® by Novocure Receives CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer

(P=0.035) in median OS. The group treated with Optune Lua concurrently with an immune checkpoint inhibitor or docetaxel (n=137) had a median OS of 13.2 months (95% CI, 10.3 to 15.5 months) compared to a median OS of 9.9 months (95% CI, 8.2 to 11.5...